Kardatuxan

Rivaroxaban, the active ingredient in Kardatuxan, is a direct factor Xa inhibitor presented as an oral tablet for oral use. It is used to reduce the risk of stroke in patients with non‑valvular atrial fibrillation and to treat or prevent deep vein thrombosis and pulmonary embolism.

GNH USA supplies Kardatuxan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rivaroxaban is a direct factor Xa inhibitor used in thromboembolic disorders.

- Non‑valvular atrial fibrillation: reduces the risk of stroke and systemic embolism. - Deep vein thrombosis (DVT): treats acute DVT and helps prevent recurrence. - Pulmonary embolism (PE): treats acute PE and reduces the risk of recurrent embolic events.

Rivaroxaban may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Bruising or minor bleeding at sites of injury. - Nosebleeds. - Gastrointestinal discomfort or dyspepsia. - Headache. - Mild anemia. - Dizziness.

Serious or Rare Side Effects: - Major bleeding, including gastrointestinal or intracranial hemorrhage. - Spinal or epidural hematoma, especially after neuraxial procedures. - Severe hepatic injury. - Allergic reactions such as rash, angioedema, or anaphylaxis. - Thrombocytopenia. - Disseminated intravascular coagulation (rare).

Before initiating therapy, consider the following safety measures.

- Renal impairment: assess renal function and adjust therapy as needed. - Hepatic disease: avoid use in patients with severe hepatic impairment. - Concomitant antiplatelet therapy: increased risk of bleeding; monitor closely. - Surgery or invasive procedures: discontinue according to clinical guidelines to reduce bleeding risk. - Elderly patients: monitor for signs of bleeding more frequently. - Store at room temperature: keep in the original container, protect from moisture and heat.

Rivaroxaban interacts with several drug classes that can alter its anticoagulant effect.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and bleeding risk. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy and increase risk of thrombotic events. - Other anticoagulants (e.g., warfarin, heparin): additive anticoagulant effect leading to major bleeding.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin, clopidogrel): heightened bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs, e.g., ibuprofen): increased gastrointestinal bleeding risk. - Selective serotonin reuptake inhibitors (SSRIs, e.g., sertraline): may potentiate bleeding.